Longeveron(US:LGVN) Newsfilter·2024-06-17 13:00Core Insights - Longeveron Inc. is a clinical stage biotechnology company focused on developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease [2][4] - The company will participate in the Virtual Life Sciences Investor Forum on June 20, 2024, with a webcast available for access on their website [2][3] - Longeveron's lead investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors, with potential applications across various disease areas [4] Company Overview - Longeveron is developing regenerative medicines to address unmet medical needs, focusing on three pipeline indications: HLHS, Alzheimer's disease, and aging-related frailty [4] - The Lomecel-B™ HLHS program has received three significant U.S. FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [4]